MIAMI, FL / ACCESSWIRE / October 21, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is…
Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is…
Celebrating its golden anniversary, Nikon Small World honors a stunning photo of brain tumor cell structures, advancing our understanding of…
Company also a finalist for Digital Health Awards to be announced on opening night BOSTON, Oct. 17, 2024 /PRNewswire/ --…
BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment…
– Topline results from Phase 2a study – Nearly 60% of all patients treated with gemlapodect and 88% of patients…
MANCHESTER, England, Oct. 15, 2024 /PRNewswire/ -- Monument Therapeutics, a precision neuroscience company, today announced a further £1M equity investment…
- Neurophet's brain MRI analysis technology incorporates fluid biomarker data from AriBio's global Phase 3 clinical trial for Alzheimer's disease…
Thought Leader in Brain Health Joins Richard Stark and Company Co-Founders to Accelerate Innovation in Precision MedicineMONTREAL, QC / ACCESSWIRE…
Toronto, Ontario--(Newsfile Corp. - October 15, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or…
